Official Title Improving Physical Ability and Cellular Senescence Elimination in HIV (IPACE-HIV)

Purpose

The purpose of this study is to evaluate the safety and tolerability of dasatinib and quercetin (D+Q) and efficacy of this regimen in improving physical function outcomes in people with HIV (PWH) who are frail or prefrail.

Could this study be right for you?

• People living with HIV ≥50 years diagnosed with HIV 10 or more years ago
• Currently on combination antiretroviral therapy
• Currently virologically suppressed
• Must meet FFP criteria & have 4-meter gait speed in the range of .5-1.2 m/sec

Age Range

50 years and up

Official Title A randomized, double-blind, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with recently diagnosed Stage 3 Type 1 Diabetes (T1D)

Purpose

This study is testing a medicine called teplizumab to see if it can help people aged 18 to 25 who were recently diagnosed with Type 1 Diabetes (T1D). The goal is to find out if teplizumab can protect the cells in the body that make insulin, which helps control blood sugar.

People with T1D usually lose these insulin-producing cells over time, and this study wants to see if teplizumab can slow down or stop that process. Everyone in the study will continue using insulin as usual, but some will also get teplizumab (or a placebo, which has no medicine) through IV infusions.

Researchers hope this treatment will:

• Help the body keep making some of its own insulin

• Reduce the amount of insulin people need to take

• Improve blood sugar control

• Lower the risk of very low blood sugar levels

The study will last about 84 weeks (a little over a year and a half), and participants will have regular checkups and tests to see how well the medicine works and how safe it is.

Could this study be right for you?

• Must be diagnosed with Type 1 Diabetes in the past 2 months
• Must have had a positive test for at least one Type 1 Diabetes antibody
• For female participants of childbearing potential - must use a contraception method (or abstinence) 

Age Range

18 - 25 years

Official Title A Multicenter, Randomized, Double-blind, Sham-controlled study for Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals with Type II Diabetes (ReCET Study)

Purpose

To test the efficacy of a one-time non-surgical endoscopic procedure on improved glycemic control in patients with type 2 diabetes who are not on insulin. 

Could this study be right for you?

Participants are eligible to be included in the study if all of the following criteria apply:
1. 22-70 years of age, inclusive.
2. T2D diagnosis for at least 6 months.
3. HbA1c of 7.5-10.5%, inclusive, determined by central laboratory. If the individual is on four glucose-lowering medications, HbA1c should be between 7.5% and 9.0%.
4. BMI 27-40 kg/m2, inclusive.
5. On 2-4 non-insulin glucose lowering mediations or on monotherapy with either GLP-1, or GLP-1/GIP medications, with no changes in medication or dosing for at least 12 weeks prior to the baseline visit.
6. Individualized metabolic surgery (IMS) score ≤ 115.
7. Weight stability (defined as a < 5% change in body weight) for at least 12 weeks prior to the screening visit.
8. Agree not to donate blood during participation in the study.
9. Able to comply with study requirements and understand and sign the Informed Consent Form.
10. Women of childbearing potential must be not pregnant and using an acceptable method of contraception throughout the study.
11. Willing and able to comply with study visits and study tasks as required per protocol.

Age Range

22 - 70 years

Official Title A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy

Purpose

This research is being done to see the effectiveness and safety of a new drug called BHV-7000 as a possible treatment for focal seizures for patients who are taking anti-seizure medications (ASMs) and still experiencing seizures. Refractory focal epilepsy is when someone continues to have focal seizures despite treatment with ASMs or other treatments.

People who take part in this study will be randomly assigned to either study medication or a placebo, will participate for up to 5 months, and the study includes up to 7 in-person visits.

Could this study be right for you?

1. Experiencing at least 4 or more observable focal seizures per month

2. Taking at least 1 and up to 3 anti-seizure medications

3. Do not have a history of cluster/repetitive seizures (which you were not able to individually count) in the past 6 months

4. Between the ages of 18 to 75

Age Range

18 - 75 years

Official Title A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Purpose

In this research study a study drug named XEN1101 is being tested for the treatment of seizures. The main purpose of this study is to determine if XEN1101 can reduce the seizure frequency and if it is safe to use.  People who take part in this study will be randomly assigned to either study medication or a placebo, will participate for up to 5 months, and includes up to 7 in-person visits.

Could this study be right for you?

1. Experiencing at least 3 PGTCS in an 8-week period

2. Have tried at least 2 anti-seizure medications without success

3. Do not have a history of cluster/repetitive seizures (which you were not able to individually count) in the past 12 months

4. 18 years old and up

Age Range

18 years and up

Official Title Identification of novel signatures of proximal changes in the severity of suicide risk states

Purpose

This study will examine how people experience mental health symptoms, distress, and suicidal thoughts in their daily lives, to identify signs that indicate that someone's suicide risk is getting worse or improving. We will recruit people who are at different levels of suicide risk.

You will be asked to complete a survey about your life experiences, mental health symptoms, suicide thoughts, and coping strategies. You will also be asked to complete short surveys on your phones several times a day for 28 days to understand how suicide risk changes over time, and you will be provided with mental health resources you can access if in crisis.

Could this study be right for you?

1. aged 18+
2. the ability to speak, read, and understand English well enough to participate in study procedures 
3. comfort with smartphone technology
4. are currently a U.S. resident
5. participants must endorse suicidal ideation in the past week
6. and/or endorse an suicide attempt, aborted attempt, or interrupted attempt within the past month

Age Range

18 - 100 years

Official Title The Foods and Oils to Repair Correct and Enhance Strength (FORCES) Study: Determining the effect of dietary oils on muscle function, strength and mass

Purpose

The purpose of the FORCES Study is to determine how dietary oils effect muscle function, strength and mass in older adults who feel their muscle function and strength has declined with age.

During this 27-week study participants will

•  Consume ~2.5 tsp of oil each day through foods

• Complete muscle function and strength testing

• Have their blood drawn

• Have their body weight and composition measured

• Have an MRI scan of your legs, if able

• Fill out questionnaires

• Collect a small amount of muscle tissue from the leg (muscle biopsy

Could this study be right for you?

Feel your muscle function, strength or mass as decreased with age

Do NOT have food allergies 

Are not taking any weight loss medications or following a weight loss program

Age Range

65 - 80 years

Official Title Phase I Study of the Safety and Feasibility of a Ketogenic Dietary Intervention to Improve Response to Immunotherapy

Purpose

This study will look at if a ketogenic diet (KD) can help treatment work better in patients with metastatic melanoma or metastatic kidney cancer. People who take part in the study will be randomly assigned to either continue eating their usual diet or trying the KD diet for 24 weeks. Participants will have blood and stool samples collected during the study. They will also test their sugar by doing daily glucose fingers sticks. Participants may be paid up to $200 for taking part in the study.

Could this study be right for you?

1. Patients with metastatic melanoma receiving first-line treatment with immunotherapy or Patients with metastatic renal cell cancer receiving first line treatment with immunotherapy.
2. Willing to give three stool samples
3. Willing to participate in a ketogenic diet (KD)

Age Range

18 years and up

Official Title The Knowledge and Perceptions of Gen Zs Regarding the Dietary Guidelines for Americans

Purpose

1. Use ideas from Social Cognitive Theory to describe Gen Zs regarding the Dietary Guidelines for Americans (DGA) 2020 to 2025
2. Explain what Gen Z knows and believes regarding the MyPlate recommendations for healthy eating related to:

• Filling half their plate with fruit and vegetables
• Filling one-quarter of their plate with lean protein, and varying the sources of protein
• Filling one-quarter of their plate with grains, making half of the grains whole grains

3. To describe the associations between demographic variables (ethnicity, education, household income, and home environment) and Gen Zs perceptions and knowledge of the DGA

Could this study be right for you?

18 to 28 years old

Live in the US

English speaker

Have access to a device that supports Zoom

Age Range

18 - 28 years

Official Title AMC-111 Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study

Purpose

This clinical trial evaluates the usefulness of using a smartphone-based HIV-specific smoking cessation intervention at the time of lung cancer screening in helping people living with HIV quit smoking. Positively Smoke Free - Mobile may help patients with HIV quit smoking.

 

In this study, you will have lung cancer screening performed via a CT scan. You will also be enrolled into a self-guided smartphone-based HIV-specific smoking cessation intervention called “Positively Smoke Free - Mobile” lasting 42 days. After starting the intervention, you will be evaluated at 3, 6, and 12 months. 

Could this study be right for you?

Must have at least a 20 pack-year history of smoking (a way to measure how much a person has smoked over time, 1 pack-year is a pack per day for a year or 2 packs of cigarettes for half a year, etc.)

Must have not had a CT scan in the past 12 months

HIV positive, and must be receiving antiretroviral therapy and have a CD4 count of at least 200cells/uL within 6 months of enrolling in the study

Able to understand and provide informed consent

Possess a smart phone that can browse the web

Not receiving any other smoking cessation interventions currently or within the prior 30 days

Female volunteers cannot be pregnant, lactating, or breast-feeding

Age Range

45 - 80 years

Official Title A Screening Study Assessing Eligibility of Idiopathic Parkinson’s Disease Patients for Potential Future Intraputamenal Transplant Study with a Dopaminergic Precursor Product

Purpose

The purpose of this screening study is to identify eligible patients with Parkinson's Disease for a clinical trial in cell transplantation to a part of the brain called the putamen.  The cell transplantation will be of precursors of dopamine producing neurons (the precursors are intended to turn into mature neurons).  

In the screening study patients will be evaluated for the following:

• To characterize your Parkinson's Disease symptoms using information from clinical assessments, genetic tests, blood tests, and imaging of the brain.
• Determine if you qualify for a future Phase 1b/2a transplant study to the putamen
• To collect imaging information about dopamine function and brain function in Parkinson's Disease using 2 scans called a F-DOPA PET and a FDG PET
• To study your blood and urine for biomarkers

Could this study be right for you?

Inclusion Criteria (summarized)

1. Diagnosis of Idiopathic Parkinson’s Disease 
2. Currently using anti-parkinsonian medications and experience some benefits from the medications.
3. Both sides of your body experience symptoms of Parkinson's Disease
4. Not currently pregnant or planning to get pregnant 
5. Willing and able to avoid deep brain stimulation (DBS) during the course of the study and for at least 18 months after transplantation should the study participant be eligible for the interventional phase
6. Willing and able to avoid treatment with continuous apomorphine IV infusions or Duodopa® during the course of the study

Exclusion Criteria (summarized)

1. Diagnosis of secondary or atypical parkinsonism.
2. Previous infusion therapy or surgery for PD.
3. Severe dyskinesia (mild to moderate levadopa induced dyskinesia is acceptable)
4. Clinically significant hallucinations requiring antipsychotic use in the previous 6 months.
5. Use of dopamine antagonists within 90 days of screening.
6. Currently active major depression that is not well controlled
7. History of any cancer (other than treated basal or squamous cell carcinoma) within past 3 years 
8.  Current participation in another investigational clinical trial and/or receipt of any investigational medication within 90 days prior to screening.
9. Known PD gene mutation or causative variant as informed by genetic testing.
10. Unable to have a MRI

Age Range

45 - 75 years

Official Title A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis suppurativa

Purpose

This study is being done to see how well remibrutinib works for people who have hidradenitis suppurativa

 

Could this study be right for you?

• Subject must have a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months with lesions in 2 distinct areas
• Subject must be in good general health with no history of tuberculosis, HIV, or hepatitis B or C
• Subject must have no recent history (within 6 months) of significant medical conditions such as a heart attack or stroke
• Subject must not be taking anticoagulant medication (ex. warfarin) or dual anti-platelet therapy (ex. acetylsalicylic acid + clopidogrel)

Age Range

18 years and up